Vmbook Online ordering
Biotechnology
Ziopharm Oncology, Inc. is a biotech company that focuses on the development and commercialization of new cancer therapies. The company's stock symbol is ZIOP, and it is listed on the NASDAQ stock exchange.
Here are some key facts about Ziopharm Oncology, Inc.:
1. Earnings: The company's net loss for the third quarter of 2022 was $20.2 million, or $0.13 per share, compared to a net loss of $14.3 million, or $0.11 per share, for the same period in 2022.
2. Revenue: Ziopharm's revenue for the third quarter of 2022 was $13.7 million, which represents a 56% increase over the same period in 2022.
3. Cash and Investments: As of September 30, 2022, the company had cash, cash equivalents, and investments of $258.5 million.
4. Pipeline: Ziopharm's pipeline includes several drug candidates in various stages of development, including gene therapies for cancer and immunotherapies.
5. Partnerships: The company has collaborated with several major pharmaceutical companies, including Merck KGaA and Pfizer, to develop and commercialize its drug candidates.
6. Growth Prospects: Ziopharm's focus on gene therapy and immunotherapy has significant growth potential, given the increasing demand for innovative cancer treatments.
7. Competition: Ziopharm competes with other biotech companies developing cancer therapies, such as Bluebird Bio, Legend Biotech, and Cellectis.
8. Analyst Coverage: Several analysts cover Ziopharm, including those from William Blair, B. Riley Securities, and Canaccord Genuity. Their price targets for ZIOP range from $13 to $20.
9. Stock Performance: ZIOP's stock price has been volatile, ranging from a low of $4.46 to a high of $14.25 in the past year.
10. Institutional Ownership: Institutional investors own approximately 69% of Ziopharm's outstanding shares, including significant stakes held by Blackrock, Vanguard, and Baker Bros. Advisors.
Note that the information provided is only current as of the date of this response and may not reflect Ziopharm's current financial status or stock performance accurately. For the most up-to-date information, please visit reputable financial websites or consult with a financial advisor.